Achieve Life Sciences Inc.
ACHV | NASDAQ
$8.31
+$0.26 (+3.23%)
Sep 22, 2026, 11:21 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 228K | 229K | n/a | n/a | n/a | 255K |
Gross Profit | -228K | -229K | n/a | n/a | n/a | -255K |
Operating Income | -54.88M | -39.07M | -27.25M | -40.8M | -33.09M | -14.75M |
Interest Income | 1.5M | 2.36M | 825K | 199K | 17K | 69K |
Pretax Income | -54.65M | -39.83M | -29.82M | -42.35M | -33.15M | -14.73M |
Net Income | -54.65M | -39.83M | -29.82M | -42.35M | -33.15M | -14.66M |
Selling & General & Admin | 31.87M | 16.25M | 11.44M | 10.72M | 9.13M | 7.61M |
Research & Development | 22.96M | 22.82M | 15.81M | 30.08M | 23.97M | 6.88M |
Other Expenses | 48K | -229K | n/a | n/a | n/a | n/a |
Operating Expenses | 54.65M | 38.84M | 27.25M | 40.8M | 33.09M | 14.5M |
Interest Expense | 819K | 2.18M | 2.85M | 1.79M | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 54.88M | 39.07M | 27.25M | 40.8M | 33.09M | 14.75M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 43.59M | 32.07M | 19.83M | 10.59M | 8.12M | 2.72M |
Shares Outstanding (Diluted) | 43.59M | 32.07M | 19.83M | 10.59M | 8.12M | 2.72M |
EPS (Basic) | -1.25 | -1.24 | -1.50 | -3.95 | -4.05 | -5.39 |
EPS (Diluted) | -1.25 | -1.24 | -1.50 | -3.95 | -4.05 | -5.39 |
EBITDA | -53.6M | -37.42M | -26.73M | -40.33M | -32.9M | -14.48M |
EBIT | -53.83M | -37.65M | -26.96M | -40.56M | -33.15M | -14.73M |
Depreciation & Amortization | 228K | 229K | 228K | 236K | 250K | 255K |
Add to Watchlist
Select watchlists to add or remove ACHV